Table of Contents
A Universal Phase, Frequently Undervalued
Menopause affects every woman who lives long enough — and with female life expectancy at 79+ years in most developed countries, most women will spend more than one-third of their lives in the post-menopause period. Despite this, research shows that fewer than 30% of women receive adequate guidance from their physician about climacteric symptoms and available treatment options.
1. Definitions: Menopause, Perimenopause and Climacteric
These terms are frequently used imprecisely. Clinical distinction matters:
- Menopause — a single event: the date of the final spontaneous menstrual period, confirmed after 12 consecutive months of amenorrhea. Occurs on average at 51 years (range: 45–55). It is a retrospective diagnosis.
- Perimenopause — the transition period beginning when menstrual cycles become irregular (typically 2–8 years before menopause) and ending 12 months after the final period. This is when symptoms are most intense.
- Climacteric — broader term encompassing perimenopause and the early post-menopause years. Period of greatest clinical intervention.
- Premature menopause — before age 40 (Primary Ovarian Insufficiency, POI); surgical menopause (bilateral oophorectomy) can occur at any age.
2. Hormonal Pathophysiology
The ovary contains a finite reserve of primordial follicles determined at birth. With aging, this reserve progressively depletes — a process called follicular depletion. When the reserve falls below a critical level, estradiol (the primary ovarian estrogen) and inhibin B production decreases, reducing negative feedback on the pituitary.
The pituitary responds by elevating FSH (Follicle-Stimulating Hormone) — the classic laboratory marker of ovarian failure. The fall in estradiol affects multiple body systems, as estrogen has receptors in tissues including the brain, bone, cardiovascular system, genitalia, skin, and bladder.
3. Symptoms: The Domains of Menopause
| Domain | Main Symptoms | Prevalence |
|---|---|---|
| Vasomotor | Hot flashes, night sweats, flushing | 75–85% |
| Sleep | Insomnia, early awakening, daytime sleepiness | 40–60% |
| Mood & Cognitive | Irritability, anxiety, depression, "brain fog," memory difficulty | 30–50% |
| Genitourinary (GSM) | Vaginal dryness, dyspareunia, atrophic vaginitis, urinary urgency, recurrent UTIs | 50–70% (post-menopause) |
| Musculoskeletal | Joint pain (arthralgia), morning stiffness, muscle mass loss | 40–60% |
| Sexual | Reduced libido, sexual dysfunction, difficulty achieving orgasm | 40–50% |
Hot Flashes: The Most Characteristic Symptom
A hot flash is a sudden sensation of intense heat, usually in the face and neck, accompanied by skin flushing, sweating, and palpitations — lasting 1–5 minutes. It affects 75–85% of women. The mechanism involves alteration of the hypothalamic thermostat mediated by estradiol decline: small temperature variations that were previously tolerated now trigger excessive heat responses.
Night sweats interrupt sleep, contributing to a cycle of fatigue, irritability, and "brain fog" — frequently misdiagnosed as isolated depression.
4. Diagnosis: When to Check FSH?
The diagnosis of menopause is clinical in women over 45 with 12 months of amenorrhea — hormonal testing is not necessary. FSH is useful in specific situations:
- Women under 45 (suspected premature menopause/POI)
- Women on hormonal contraceptives (which mask menstrual irregularity)
- Women who have undergone hysterectomy without oophorectomy
- When there is diagnostic uncertainty with other causes of amenorrhea
An FSH > 40 IU/L on two measurements, 4–6 weeks apart, confirms ovarian failure in women under 40 (POI). In perimenopausal women, FSH can fluctuate — a single elevated result does not confirm menopause.
5. Hormone Replacement Therapy (HRT): Post-WHI Update
The Women's Health Initiative (WHI, 2002) caused a global negative impact on HRT by reporting increased breast cancer and cardiovascular disease risk. But re-analysis of the data showed these findings applied specifically to older women (average age 63) who started HRT more than 10 years after menopause — not the profile of symptomatic women in perimenopause.
The "Window of Opportunity" (Timing Hypothesis): when started within the first 10 years after menopause or before age 60, HRT has a favorable cardiovascular safety profile (reduces early-stage atherosclerosis).
| Route of Administration | Advantages | Considerations |
|---|---|---|
| Oral (tablet) | Convenient; good adherence; reduces LDL | Hepatic first-pass effect; slightly higher DVT and stroke risk vs. transdermal |
| Transdermal (patch/gel/spray) | Bypasses hepatic metabolism; no increase in DVT risk; equally controls hot flashes | Skin irritation with patch; variable cost |
| Vaginal (cream/ring/suppository) | Local effect for GSM; minimal systemic absorption; can be used alone for GSM | Does not control hot flashes; endometrial protection not needed at low topical doses |
Progesterone/progestogen: Women with an intact uterus need progestogen added to estrogen to protect the endometrium from hyperplasia/cancer. Micronized natural progesterone (Utrogestan) has a more favorable breast safety profile than synthetic progestogens, according to data from the Million Women Study and WHI.
6. Cardiovascular Risk & Osteoporosis in Post-Menopause
Before menopause, women have significantly lower cardiovascular risk than men. After menopause, this protection is lost — estrogen protected the vascular endothelium, reduced LDL, and raised HDL. In post-menopause, coronary artery disease risk equalizes with men around age 70.
Postmenopausal osteoporosis is a direct consequence of estrogen deficiency: estrogen inhibits osteoclasts (bone-resorbing cells). With its decline, bone remodeling becomes unbalanced, with resorption exceeding formation. Women lose an average of 2–4% of bone mineral density per year in the first 5–7 years after menopause.
HRT is the most effective treatment for osteoporosis prevention in symptomatic women — reducing vertebral and hip fractures by 30–40%. Asymptomatic women with osteoporosis have specific alternatives: bisphosphonates, denosumab, or SERMs (raloxifene).
7. Non-Hormonal Options for Hot Flashes
For women with contraindications to HRT (hormone-sensitive breast cancer, recent VTE, severe liver disease) or who prefer not to use hormones:
- SSRIs/SNRIs — paroxetine (FDA-approved), venlafaxine, desvenlafaxine: reduce hot flashes by 50–65%.
- Gabapentin — reduces hot flashes, especially nocturnal ones. Useful when comorbid chronic pain or insomnia.
- Fezolinetant (FDA-approved 2023) — NK3 receptor antagonist. First non-hormonal drug specifically for hot flashes; 60–75% reduction in frequency. Revolutionary for women with hormonal contraindications.
- Phytoestrogens (soy isoflavones, black cohosh) — moderate evidence; highly variable individual response.
8. Lifestyle in Menopause: What Science Says
- Exercise: strength training 2–3x/week is essential to preserve muscle mass (sarcopenia prevention) and bone density. Aerobic exercise reduces hot flashes and improves sleep and mood.
- Weight management: women with overweight have more frequent and severe hot flashes. Adipose tissue produces estrones (weak estrogens) that may initially attenuate hot flashes but increase risk of breast and endometrial cancer.
- Diet: rich in calcium (1200 mg/day via food), vitamin D (1500–2000 IU/day), protein (≥1.2g/kg), and omega-3. Mediterranean diet reduces cardiovascular risk and improves metabolic profile in menopause.
- No smoking: tobacco accelerates menopause by 1–2 years and worsens hot flashes.
- Reduce alcohol: alcohol worsens hot flashes and insomnia and increases breast cancer risk.
- Sleep hygiene: cool bedroom temperatures, cotton clothing, avoid hot flash triggers (caffeine, spicy foods, red wine).
References
1. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794.
2. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA. 2002;288(3):321-333.
3. Manson JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA. 2017;318(10):927-938.
4. Stuenkel CA, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
5. Johnson A, Roberts L, Elkins G. Complementary and Alternative Medicine for Menopause. J Evid Based Integr Med. 2019;24:2515690X19829380.
6. Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038-1062.
7. Lobo RA. Menopause: Recent and Future Perspectives. Annu Rev Med. 2017;68:245-254.
8. Peacock K, Ketvertis KM. Menopause. StatPearls. 2023.